{"id":"desferrioxamine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Desferal, desferoxamine"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha"},"_scrapedAt":"2026-03-28T01:09:06.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic Iron Overload","diseaseId":"chronic-iron-overload","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Poisoning by iron AND/OR its compounds","diseaseId":"poisoning-by-iron-and/or-its-compounds","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06650163","phase":"PHASE1","title":"Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-05","conditions":"Glioma, Malignant Brain Neoplasm, Meningioma","enrollment":20},{"nctId":"NCT05371132","phase":"PHASE1","title":"Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-20","conditions":"Metastatic Malignant Solid Neoplasm, Lymphoma","enrollment":10},{"nctId":"NCT04566991","phase":"PHASE2","title":"Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)","status":"RECRUITING","sponsor":"Aditya S. Pandey, MD","startDate":"2022-03-20","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":120},{"nctId":"NCT07023666","phase":"PHASE2","title":"Early Screening and Treatment of Heart Complication in Sickle Cell Disease","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-10-07","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT07162363","phase":"PHASE2, PHASE3","title":"Synergistic Minimally Invasive Surgery and Deferoxamine in ICH","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage","enrollment":240},{"nctId":"NCT06763055","phase":"PHASE3","title":"The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-02-27","conditions":"Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage, Supratentorial Intracerebral Haemorrhage","enrollment":2000},{"nctId":"NCT06204237","phase":"EARLY_PHASE1","title":"Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)","status":"RECRUITING","sponsor":"Aplagon Oy","startDate":"2024-02-01","conditions":"Peripheral Arterial Occlusive Disease, Critical Limb Ischemia","enrollment":10},{"nctId":"NCT06750419","phase":"PHASE3","title":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-11-06","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":82},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT00749515","phase":"PHASE4","title":"Pilot Study for Patients With Poor Response to Deferasirox","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2008-03","conditions":"Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease","enrollment":15},{"nctId":"NCT02875262","phase":"PHASE1, PHASE2","title":"Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-12-02","conditions":"Intracranial Aneurysm, Subarachnoid Hemorrhage","enrollment":40},{"nctId":"NCT00000588","phase":"PHASE2","title":"Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"1989-06-05","conditions":"Anemia (Iron-Loading), Beta-Thalassemia, Hematologic Diseases","enrollment":120},{"nctId":"NCT03085771","phase":"PHASE2","title":"Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2017-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT03137966","phase":"PHASE2","title":"Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers","status":"NOT_YET_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2022-12-30","conditions":"Diabetic Foot Ulcer","enrollment":174},{"nctId":"NCT00110266","phase":"PHASE2","title":"Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-07-25","conditions":"Myelodysplastic Syndrome, Iron Overload","enrollment":176},{"nctId":"NCT00901199","phase":"PHASE2","title":"Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload","status":"COMPLETED","sponsor":"Elliott Vichinsky","startDate":"2007-09","conditions":"Thalassemia, Iron Overload","enrollment":22},{"nctId":"NCT00447694","phase":"PHASE2","title":"Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02","conditions":"Beta-thalassemia, Iron Overload","enrollment":30},{"nctId":"NCT04361032","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","status":"UNKNOWN","sponsor":"Abderrahmane Mami Hospital","startDate":"2020-09-04","conditions":"COVID19, Intensive Care Unit","enrollment":260},{"nctId":"NCT04389801","phase":"PHASE4","title":"Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection","status":"UNKNOWN","sponsor":"Hesham Al-Inany","startDate":"2020-06-01","conditions":"Covid 19","enrollment":200},{"nctId":"NCT04333550","phase":"PHASE1, PHASE2","title":"Application of Desferal to Treat COVID-19","status":"UNKNOWN","sponsor":"Kermanshah University of Medical Sciences","startDate":"2020-04","conditions":"COVID-19","enrollment":50},{"nctId":"NCT00001203","phase":"","title":"Deferoxamine for the Treatment of Hemochromatosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1985-04-22","conditions":"Diabetes Mellitus, Heart Disease, Hemochromatosis","enrollment":151},{"nctId":"NCT01459718","phase":"PHASE2","title":"Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload","enrollment":32},{"nctId":"NCT01662895","phase":"PHASE2","title":"High-Dose Deferoxamine in Intracerebral Hemorrhage","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2013-03-18","conditions":"Intracerebral Hemorrhage","enrollment":42},{"nctId":"NCT02175225","phase":"PHASE2","title":"Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-10","conditions":"Intracerebral Hemorrhage","enrollment":294},{"nctId":"NCT00598572","phase":"PHASE1","title":"Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-07","conditions":"Intracerebral Hemorrhage","enrollment":20},{"nctId":"NCT02065492","phase":"PHASE2, PHASE3","title":"Amlodipine for Myocardial Iron in Thalassemia","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2014-02","conditions":"Thalassemia","enrollment":20},{"nctId":"NCT00105495","phase":"PHASE4","title":"Efficacy Study in Removing Excess Iron From the Heart","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2002-12","conditions":"Thalassemia Major, Hemosiderosis","enrollment":60},{"nctId":"NCT02216513","phase":"EARLY_PHASE1","title":"Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2014-09","conditions":"Subarachnoid Hemorrhage","enrollment":2},{"nctId":"NCT02367248","phase":"PHASE1, PHASE2","title":"Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2015-03","conditions":"Intracerebral Hemorrhage","enrollment":180},{"nctId":"NCT01365104","phase":"EARLY_PHASE1","title":"Modulation of Cerebral Blood Flow Using Iron Chelators","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-03","conditions":"Stroke, Problem of Aging","enrollment":97},{"nctId":"NCT01996683","phase":"NA","title":"Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-11","conditions":"Beta-thalassemia, Serum Ferritin, Iron Chelation Therapy","enrollment":50},{"nctId":"NCT00000595","phase":"PHASE2","title":"Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1978-01","conditions":"Anemia (Iron-Loading), Beta-Thalassemia, Hematologic Diseases","enrollment":""},{"nctId":"NCT00658411","phase":"NA","title":"Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2008-08","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT01752153","phase":"PHASE1","title":"Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2012-06","conditions":"Immune Abnormalities","enrollment":25},{"nctId":"NCT00350662","phase":"PHASE3","title":"Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients","status":"COMPLETED","sponsor":"Lipomed","startDate":"2002-01","conditions":"Hemochromatosis","enrollment":95},{"nctId":"NCT00293098","phase":"","title":"Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Children's Hospital of Philadelphia","startDate":"2006-03","conditions":"Iron Overload","enrollment":""},{"nctId":"NCT01511848","phase":"PHASE2, PHASE3","title":"Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2012-02","conditions":"Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis","enrollment":60},{"nctId":"NCT00349453","phase":"PHASE2","title":"Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients","status":"COMPLETED","sponsor":"Lipomed","startDate":"2005-03","conditions":"Hemochromatosis","enrollment":24},{"nctId":"NCT01369719","phase":"NA","title":"Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload","status":"COMPLETED","sponsor":"Hormozgan University of Medical Sciences","startDate":"2010-02","conditions":"Thalassemia, Iron Overload, Transfusion Related Complications","enrollment":138},{"nctId":"NCT00738413","phase":"PHASE1, PHASE2","title":"Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both","status":"UNKNOWN","sponsor":"Weill Medical College of Cornell University","startDate":"2008-08","conditions":"Thalassemia","enrollment":6},{"nctId":"NCT00999349","phase":"PHASE2, PHASE3","title":"Therapeutic Effects of Silymarin in Patients With B-thalassemia Major","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2009-03","conditions":"Beta-thalassemia Major, Iron Overload","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":3983,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"desferrioxamine","genericName":"desferrioxamine","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}